Physicians' Academy for Cardiovascular Education

ESC 2016

PACE-CME.org was present at the ESC 2016 in Rome. Find coverage of the latest CV news on PACE-CME.

Would lower than the current ApoB targets be more useful for clinical decision-making?

10' education - Aug. 29, 2016 - ESC Rome, Italy - Seth Shay Martin, MD (Baltimore, MD, VS) and Allan Sniderman, MD (Montreal, Quebec, Canada).

Understanding why patients do not take their medication and stimulating adherence

10' education - Aug. 27, 2016 - ESC Rome, Italy - Prof. Robert Horne (London, United Kingdom)
##SCROLLER_ITEMS_FULL_TITLE##

Iron deficiency in the new HF guidelines

3' education - Aug. 29, 2016 - Peter van der Meer, MD - University Medical Center Groningen, The Netherlands

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)
##SCROLLER_ITEMS_FULL_TITLE##

Extra work of checking device data weekly does not translate into benefit for HF patient

3' education - Oct. 25, 2016 - ESC - 2016 Rome - Martin Cowie, MD - National Heart & Lung Institute, London, UK
##SCROLLER_ITEMS_FULL_TITLE##

Customising therapy approach in ACS based on underlying pathology seems promising

3' education - Oct. 21, 2016 - ESC - 2016 Rome - Ik-Kyung Jang, MD - Massachusetts General Hospital, Boston, MA, USA

Interim results of new device for treatment resistant hypertension

10' education - Aug. 29, 2016 - ESC Rome, Italy - Dr. Wilko Spiering (Utrecht, The Netherlands)

Targeting residual inflammatory risk as a strategy to lower CV risk

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Paul Ridker (Boston, MA, USA)
##SCROLLER_ITEMS_FULL_TITLE##

Heart failure news at the ESC

10' education - Aug. 29, 2016 - ESC - 2016 Rome - Frank Ruschitzka, MD - University Heart Center, Zurich, Switzerland
##SCROLLER_ITEMS_FULL_TITLE##

No indication for difference in efficacy between potent platelet inhibitors after PCI

3' education - Aug. 30, 2016 - ESC - 2016 Rome - Steen Dalby Kristensen, MD - Aarhus University, Denmark

To SPRINT or not to SPRINT to a lower blood pressure target?

10' education - Aug. 29, 2016 - ESC Rome, Italy - William C Cushman (Memphis, TN, USA) and Sverre E Kjeldsen (Oslo, Norway)

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

10' education - Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

Beyond statins: The role of ezetimibe in targeting residual risk

10' education - Aug. 29, 2016 - ESC 2016, Rome - Chris Packard, MD – University of Glasgow, United Kingdom

Inflammation as potential target for therapy to target residual risk post ACS

10' education - Aug. 27, 2016 - ESC 2016, Rome - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
##SCROLLER_ITEMS_FULL_TITLE##

Mendelian randomisation study suggests that CV prevention could be simpler and more effective

3' education - Sep. 21, 2016 - ESC - 2016 Rome - Dr. Brian Ference (Detroit, MI, VS)
##SCROLLER_ITEMS_FULL_TITLE##

Heart Failure news from ESC 2016 at a glance

3' education - Sep. 21, 2016 - ESC - 2016 Rome - Prof. Mariell Jessup (Philadelphia, PA, USA)

A clinical perspective on PCSK9 inhibition: What do we know an what can we expect?

10' education - Aug. 27, 2016 - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

PCSK9, the short track road from discovery as drug target towards the clinic

10' education - Aug. 27, 2016 - ESC 2016, Rome - Gilles Lambert, MD – Université de la Réunion, Sainte-Clotilde, France

Epigenetics: A closer look at BET inhibition

Sep. 5, 2016

Understanding BET inhibition as a novel pathway for cardiovascular risk modulation

10' education - Aug. 28, 2016 - ESC 2016, Rome - Jorge Plutzky, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA - Recorded at PACE-CME symposium at ESC 2016

BET inhibition in cardiovascular disease: A new dawn?

10' education - Aug. 28, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands - Recorded at PACE-CME symposium at ESC 2016

The high risk diabetes patient with cardiovascular disease: What else can we target to reduce cardiovascular risk?

10' education - Aug. 28, 2016 - ESC 2016, Rome - Kausik Ray, MD – Imperial College London, United Kingdom - Recorded at PACE-CME symposium at ESC 2016

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

10' education - Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands

Would lower than the current ApoB targets be more useful for clinical decision-making?

10' education - Aug. 29, 2016 - ESC Rome, Italy - Seth Shay Martin, MD (Baltimore, MD, VS) and Allan Sniderman, MD (Montreal, Quebec, Canada).
Lower than the currently recommended ApoB targets may be more useful for clinical decision-making.

CSI Rome Analysis of ApoB levels in the NHANES population revealed that guideline recommended ApoB targets have limited value in clinicial practice. Lotte Koopal and Gijs Berkelmans discuss these insights with Dr. Seth Shay Martin and Dr. Allan Sniderman.

Understanding why patients do not take their medication and stimulating adherence

10' education - Aug. 27, 2016 - ESC Rome, Italy - Prof. Robert Horne (London, United Kingdom)

CSI Rome Robert Horne is a Professor of Behavioural Medicine at University College London, United Kingdom who studies treatment non-adherence. Monique van Kleef discusses with him why this is a particular problem in hypertension, and how this may be improved.

Iron deficiency in the new HF guidelines

3' education - Aug. 29, 2016 - Peter van der Meer, MD - University Medical Center Groningen, The Netherlands
##OVERVIEW_ITEMS_KEY_PHRASE##

Iron deficiency impairs quality of life and exercise capacity in heart failure patients. The new ESC HF guidelines recommend measuring and treating iron deficiency to help these patients.

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)
CV benefit that can be achieved with the new glucose-lowering SGLT2-inhibitor empagliflozin in diabetes

CSI Rome Manon Slob and Shahnam Sharif extensively discuss the results of the EMPA-REG OUTCOME study, the first outcomes trial with an SGLT2 inhibitor, with Prof. Silvio Inzucchi, including what the results may mean for the management of diabetes.

Extra work of checking device data weekly does not translate into benefit for HF patient

ESC - 2016 Rome

3' education - Oct. 25, 2016 - ESC - 2016 Rome - Martin Cowie, MD - National Heart & Lung Institute, London, UK
##OVERVIEW_ITEMS_KEY_PHRASE##

Martin Cowie shares the very clear results of the REM-HF study addressing the question whether outcome can be improved in patients with heart failure with an implanted device, if device data are collected remotely on a weekly basis.

Customising therapy approach in ACS based on underlying pathology seems promising

ESC - 2016 Rome

3' education - Oct. 21, 2016 - ESC - 2016 Rome - Ik-Kyung Jang, MD - Massachusetts General Hospital, Boston, MA, USA
##OVERVIEW_ITEMS_KEY_PHRASE##

ESC 2016 Dr. Ik-Kyuang Jang shares the insights gained from a pilot study that tested a new therapeutic approach in patients with ACS induced by plaque erosion, namely to give drug therapy instead of placing a stent.

Interim results of new device for treatment resistant hypertension

10' education - Aug. 29, 2016 - ESC Rome, Italy - Dr. Wilko Spiering (Utrecht, The Netherlands)
FIrst results of the CALM-FIM study, a first-in-man study with a new device (MobiusHD) for patients with treatment resistant hypertension.

CSI ROME Nicolette van der Sande and Monique van Kleef question Wilko Spiering about the interim results of the CALM-FIM study. This was a first-in-man study with a new device (MobiusHD) for patients with treatment resistant hypertension.

Targeting residual inflammatory risk as a strategy to lower CV risk

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Paul Ridker (Boston, MA, USA)
Residual CV risk consists of cholesterol and inflammatory residual risk. How can these aspects be addressed to lower CV risk?

CSI ROME Nicole Jaspers and Manon Slob interview Prof. Paul Ridker about the concept of residual risk and how the different forms may be targeted with novel therapeutic strategies to further lower CV risk.

No indication for difference in efficacy between potent platelet inhibitors after PCI

3' education - Aug. 30, 2016 - ESC - 2016 Rome - Steen Dalby Kristensen, MD - Aarhus University, Denmark
##OVERVIEW_ITEMS_KEY_PHRASE##

ESC 2016 The PRAGUE-18 study was a direct comparison between the potent P2Y12 inhibitors prasugrel and ticagrelor. While the study was stopped early due to futility, Steen Dalby Kristensen thinks that there is no major difference between the two agents.

To SPRINT or not to SPRINT to a lower blood pressure target?

10' education - Aug. 29, 2016 - ESC Rome, Italy - William C Cushman (Memphis, TN, USA) and Sverre E Kjeldsen (Oslo, Norway)
Two professors disagree on whether the results of the SPRINT trial on blood pressure lowering should influence new guidelines.

CSI ROME Nicolette van der Sande and Monique van Kleef critically discuss the SPRINT trial results with William Cushman and Sverre Kjeldsen. The professors disagree on whether these results should influence new guidelines.

Mendelian randomisation study suggests that CV prevention could be simpler and more effective

3' education - Sep. 21, 2016 - ESC - 2016 Rome - Dr. Brian Ference (Detroit, MI, VS)
##OVERVIEW_ITEMS_KEY_PHRASE##

ESC 2016 Dr. Brian Ference (Detroit, MI, VS) shares the results of a long-term Mendelian randomisation study that suggests that even a mild reduction of both LDL-c levels and SBP can dramatically lower CV event risk.

Heart Failure news from ESC 2016 at a glance

3' education - Sep. 21, 2016 - ESC - 2016 Rome - Prof. Mariell Jessup (Philadelphia, PA, USA)
##OVERVIEW_ITEMS_KEY_PHRASE##

ESC 2016 Prof. Mariell Jessup (Philadelphia, PA, USA) chaired the ESC Hot Line sesion on Heart Failure. She summarises the findings of remote monitoring studies and stem cell trial and touches upon the discussion this raised.